BioArctic

BioArctic EBITDA Margin

The EBITDA Margin of BioArctic (BIOA B.ST) as of Nov 9, 2026 is 68.44 %. In the previous year, EBITDA Margin was -88.79 % — a change of -177.07% (higher).

EBITDA Margin

68.44 %

YoY

-177.07%

Last updated:

EBITDA Margin of BioArctic is 2025 68.44 % . EBITDA Margin of BioArctic was 2024 -88.79 % . It decreases by -177.07% higher compared to the previous year.

The BioArctic EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
68.33 SEK
Jan 1, 2019
43.54 SEK
Jan 1, 2020
-119.62 SEK
Jan 1, 2021
-546.19 SEK
Jan 1, 2022
1.96 SEK
Jan 1, 2023
44.00 SEK
Jan 1, 2024
-88.79 SEK
Jan 1, 2025
68.44 SEK
The BioArctic EBITDA Margin history
YEAREBITDA MarginYoY
68.44 %-177.07%
-88.79 %-301.78%
44.00 %+2,145.40%
1.96 %-100.36%
-546.19 %+356.60%
-119.62 %-374.76%
43.54 %-36.29%
68.33 %+339.66%
15.54 %-78.45%
72.14 %+370.06%
15.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioArctic Stock analysis

What does BioArctic do? BioArctic AB is a Swedish biotechnology company founded in 2003. The company is based in Stockholm and focuses on the development of innovative therapeutics for nervous system diseases such as Alzheimer's, Parkinson's, and spinal cord injuries. The company uses its expertise in biological and chemical drug research to discover and develop new therapeutic possibilities, with a focus on Amyloid-Beta production. BioArctic's business strategy is based on partnerships with pharmaceutical and biotech companies worldwide, working closely with partners to develop therapies and products that meet the needs and expectations of patients and doctors. BioArctic conducts research in three different areas: Alzheimer's, Parkinson's, and spinal cord injuries. The company works with partners such as Nutricia, Eisai, Just Biotherapeutics, Abcam, Neuropharm, AbbVie, Q-Med, Uppsala University, and the Karolinska Institute to develop treatments for these conditions. BioArctic has already brought several promising products to market, including BAN2401 for Alzheimer's and SC0806 for spinal cord injuries. Overall, BioArctic is a leading company in biological and chemical drug research, with a focus on developing new therapies and products for the benefit of patients and doctors worldwide. BioArctic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioArctic stock

EBITDA Margin of BioArctic is 68.44 % in 2025.

EBITDA Margin of BioArctic changed from -88.79 % to 68.44 %, representing a -177.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin BioArctic since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's BioArctic with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioArctic

All Key Metrics — BioArctic